Patents by Inventor Robert A. Kramer

Robert A. Kramer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11925991
    Abstract: A milling device for machining a slot into an inner surface of a casing for a gas turbine engine. The milling device includes a frame assembly including multiple structural guides configured to engage structural features on the inner surface of the casing to maintain an axial position of the milling device relative to a longitudinal axis of the casing. The milling device also includes a milling cutter coupled to the frame assembly. The milling device is configured to be displaced in a circumferential direction relative to the longitudinal axis to machine the slot, via the milling cutter, along the inner surface of the casing in the circumferential direction.
    Type: Grant
    Filed: July 14, 2022
    Date of Patent: March 12, 2024
    Assignee: GENERAL ELECTRIC COMPANY
    Inventors: Kurt Kramer Schleif, Fabian Gubelmann, Andrew David Ellis, Robert David Jones, Thomas Gloor, Roman Stefan Peter
  • Publication number: 20240023527
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Application
    Filed: September 1, 2023
    Publication date: January 25, 2024
    Applicant: Merus N.V.
    Inventors: Ton LOGTENBERG, Mark Throsby, Robert A. Kramer, Rui D. Pinto, Cornelis A. De Kruif, Erwin Houtzager
  • Patent number: 11785924
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: October 17, 2023
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. De Kruif, Erwin Houtzager
  • Patent number: 11559049
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: January 24, 2023
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui D. Pinto, Cornelis A. De Kruif, Erwin Houtzager
  • Publication number: 20220340937
    Abstract: Processes and systems for biologically producing hydrogen gas from organic waste, including food waste. Such a process includes biologically producing hydrogen gas from organic waste by anaerobic fermentation of the organic waste with at least one strain of yeast.
    Type: Application
    Filed: September 25, 2020
    Publication date: October 27, 2022
    Inventors: Robert A. Kramer, Libbie S.W. Pelter, John A. Patterson
  • Patent number: 11445710
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: September 20, 2022
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui D. Pinto, Cornelis A. De Kruif, Erwin Houtzager
  • Publication number: 20220075022
    Abstract: A configurable phased array tile is disclosed including an aperture assembly having a plurality of aperture assembly connectors, a backplane assembly having a plurality of backplane assembly connectors, and a plurality of vertical transmit cards mounted to a corresponding first plurality of aperture assembly connectors and a corresponding first plurality of backplane assembly connectors. The plurality of vertical transmit cards each include a plurality of transmit channels including at least one high power transmit amplifier for powering at least one radiating element mounted to the aperture assembly.
    Type: Application
    Filed: February 4, 2021
    Publication date: March 10, 2022
    Applicant: MACOM Technology Solutions Holdings, Inc.
    Inventors: Yasser Al-Rashid, Christopher Dirk Weigand, Daniel Robert Kramer, Nicholas James Ahlquist
  • Patent number: 11237165
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: February 1, 2022
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. de Kruif, Erwin Houtzager
  • Publication number: 20210347995
    Abstract: A product for incorporating ultraviolet radiation protection and antimicrobial protection into a synthetic polymer is disclosed which has a quantity of zinc oxide particles with each particle having a surface, a paste, a quantity of synthetic polymer chips, and a quantity of a reactive group for modifying each surface of each zinc oxide particle, the quantity of the reactive group sufficient for forming a bond with the quantity of synthetic polymer chips prior to the quantity of synthetic polymer chips being formed into a fiber.
    Type: Application
    Filed: May 24, 2021
    Publication date: November 11, 2021
    Inventors: Robert Kramer, Ronald Kramer, Nicholas Marshall, Peter Hauser, Jason Rosenberg
  • Patent number: 10966411
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Grant
    Filed: October 19, 2009
    Date of Patent: April 6, 2021
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. de Kruif, Erwin Houtzager
  • Publication number: 20200319181
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 8, 2020
    Applicant: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. De Kruif, Erwin Houtzager
  • Patent number: 10605808
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: March 31, 2020
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. Dekruif, Erwin Houtzager
  • Patent number: 10284626
    Abstract: The embodiments described herein generally relate to a protocol for implementing data operations, e.g., a version of SMB, atop RDMA transports. In embodiments, systems and methods use the protocol definition, which specifies new messages for negotiating an RDMA connection and for transferring SMB2 data using the negotiated communication. A new protocol message may include new header information to determine message size, number of messages, and other information for sending the SMB2 data over RDMA. The header information is used to accommodate differences in message size requirements between RDMA and SMB2. The SMB Direct protocol allows SMB2 data to be fragmented into multiple individual RDMA messages that a receiver may then logically concatenate into a single SMB2 request or SMB2 response. The SMB Direct protocol also may allow SMB2 to transfer application data via efficient RDMA direct placement and to signal the application data's availability when the transfer is complete.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: May 7, 2019
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Thomas M. Talpey, Gregory Robert Kramer, David Matthew Kruse
  • Patent number: 10246724
    Abstract: Various embodiments of the present invention pertain to methods for biological production of hydrogen. More specifically, embodiments of the present invention pertain to a modular energy system and related methods for producing hydrogen using organic waste as a feed stock.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: April 2, 2019
    Assignee: Purdue Research Foundation
    Inventors: Robert Kramer, Libbie S. Pelter, John A. Patterson
  • Publication number: 20180142006
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Application
    Filed: January 12, 2018
    Publication date: May 24, 2018
    Applicant: Merus N.V.
    Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui D. PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
  • Publication number: 20180142005
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Application
    Filed: January 12, 2018
    Publication date: May 24, 2018
    Applicant: Merus N.V.
    Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui D. PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
  • Publication number: 20180142003
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Application
    Filed: January 9, 2018
    Publication date: May 24, 2018
    Applicant: Merus N.V.
    Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui Daniel PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
  • Publication number: 20180142002
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Application
    Filed: January 5, 2018
    Publication date: May 24, 2018
    Applicant: Merus N.V.
    Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui Daniel PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
  • Publication number: 20180134770
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Application
    Filed: January 12, 2018
    Publication date: May 17, 2018
    Applicant: Merus N.V.
    Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui D. PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
  • Patent number: 9944695
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: April 17, 2018
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. De Kruif, Erwin Houtzager